In other words, unlike the VEGF-driven increase in permeability at the core of the blood–tumor barrier, medication distribution to the periphery of the tumor is severely limited since these areas usually have an intact or only slightly compromised BBB. The gene discussed is VEGFA; the disease is neoplasm.